Table 3.
Univariate and multivariate Cox proportional hazards analyses of MK3 expression and overall survival for glioma patients.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | p-Value | Hazard ratio (95% CI) | p-Value | ||
| WHO grade | 634 | ||||
| G2 | 223 | Reference | |||
| G3 | 243 | 2.999 (2.007–4.480) | <0.001 | 1.979 (1.257–3.117) | 0.003 |
| G4 | 168 | 18.615 (12.460–27.812) | <0.001 | 6.842 (2.174–21.535) | 0.001 |
| IDH status | 685 | ||||
| WT | 246 | Reference | |||
| Mut | 439 | 0.117 (0.090–0.152) | <0.001 | 0.495 (0.289–0.849) | 0.011 |
| 1p/19q codeletion | 688 | ||||
| Codel | 170 | Reference | |||
| Non-codel | 518 | 4.428 (2.885–6.799) | <0.001 | 1.591 (0.911–2.779) | 0.103 |
| Primary therapy outcome | 461 | ||||
| CR | 138 | Reference | |||
| PR | 64 | 1.275 (0.442–3.680) | 0.653 | 1.182 (0.352–3.974) | 0.787 |
| PD | 112 | 7.500 (3.598–15.634) | <0.001 | 5.803 (2.696–12.492) | <0.001 |
| SD | 147 | 3.299 (1.528–7.123) | 0.002 | 2.115 (0.939–4.765) | 0.071 |
| Gender | 695 | ||||
| Female | 297 | Reference | |||
| Male | 398 | 1.262 (0.988–1.610) | 0.062 | 1.810 (1.156–2.832) | 0.009 |
| Age | 695 | ||||
| ≤60 | 552 | Reference | |||
| >60 | 143 | 4.668 (3.598–6.056) | <0.001 | 4.216 (2.562–6.938) | <0.001 |
| MK3 | 695 | ||||
| Low | 348 | Reference | |||
| High | 347 | 3.037 (2.349–3.927) | <0.001 | 0.926 (0.587–1.460) | 0.740 |
CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease.